Breaking Down SG&A Expenses: Amicus Therapeutics, Inc. vs MannKind Corporation

Biotech Giants' SG&A Expenses: A Decade of Divergence

__timestampAmicus Therapeutics, Inc.MannKind Corporation
Wednesday, January 1, 20142071700079383000
Thursday, January 1, 201547269000108402000
Friday, January 1, 20167115100046928000
Sunday, January 1, 20178867100074959000
Monday, January 1, 201812720000079716000
Tuesday, January 1, 201916986100074669000
Wednesday, January 1, 202015640700059040000
Friday, January 1, 202119271000077417000
Saturday, January 1, 202221304100091473000
Sunday, January 1, 202327527000094314000
Loading chart...

Unleashing insights

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing expenses is crucial for survival and growth. Amicus Therapeutics, Inc. and MannKind Corporation, two prominent players in the industry, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Amicus Therapeutics has seen a staggering increase of over 1,200% in SG&A expenses, reflecting its aggressive expansion and investment in operational capabilities. In contrast, MannKind Corporation's SG&A expenses have remained relatively stable, with a modest increase of about 19% over the same period. This divergence highlights different strategic approaches: Amicus's focus on scaling operations versus MannKind's emphasis on maintaining cost efficiency. As the biotech landscape evolves, these financial strategies will play a pivotal role in shaping the future trajectories of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025